Long term event-free survival following cell-based therapy in patients with cardiomyopathy: the HYPERION observational cohort
In this long-term observational cohort analysis, improvement of LVEF and/or reduction in LVEDV was associated with survival benefits among subjects with NIDCM and ICM, respectively. In both etiologies the respective improvements are sustained for up to 5 years, providing evidence that cell-based therapy may be a promising and durable treatment option for patients with heart failure.
Authors
- Jeanette Soto
- Aisha Khan (ORCID: https://orcid.org/0000-0001-7409-9208)
- Lina V. Caceres
- Andrew Sundin (ORCID: https://orcid.org/0000-0002-9539-1248)
- Raul D. Mitrani (ORCID: https://orcid.org/0000-0003-4337-9834)
- Maria A Cabreja
- Ivonne Hernandez Schulman (ORCID: https://orcid.org/0000-0002-2814-2321)
- Russell Saltzman (ORCID: https://orcid.org/0000-0003-0494-3869)
- Dushyantha Jayaweera (ORCID: https://orcid.org/0000-0002-4142-2002)
- Jairo A Tovar (ORCID: https://orcid.org/0000-0003-1094-2571)
- Joshua M. Hare (ORCID: https://orcid.org/0000-0002-7751-5032)
- Ana Maria Garzon
- Hossein Shayestehyekta
Institutions
- Loma Linda University Medical Center (US)
- National Institutes of Health (US)
- University of Miami (US)
- Loma Linda University (US)
- National Institute of Diabetes and Digestive and Kidney Diseases (US)
Publication Details
- Journal
- Stem Cells Translational Medicine
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1093/stcltm/szaf010
- Citations
- 1
- Primary Topic
- Cardiac Structural Anomalies and Repair
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- National Institutes of Health